Crinetics Pharmaceuticals Inc.
Clinical trials sponsored by Crinetics Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing therapies for endocrine diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill could tame rare hormone disorder
Disease control CompletedThis study tested a new oral drug called atumelnant in 38 adults with classic congenital adrenal hyperplasia, a genetic condition causing hormone imbalances. The drug works by blocking a hormone receptor to lower excess adrenal hormones. Researchers measured safety, side effects,…
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill could ease carcinoid syndrome Flare-Ups
Symptom relief CompletedThis Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Healthy volunteers help test new Drug's safety
Knowledge-focused CompletedThis study tested a new drug called atumelnant in 21 healthy adults from Japanese and Caucasian backgrounds. The goal was to see how the drug moves through the body and if it is safe. Participants took the drug or a placebo by mouth once daily. This early-stage study does not aim…
Phase: PHASE1 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC